High Roller Technologies has partnered with Kindbridge Behavioral Health to provide specialized behavioral health support for U.S. customers and employees involved in prediction markets. The program offers a free initial counseling session to eligible traders, with additional care funded by High Roller for those with insufficient insurance. It also includes quarterly customer service training on responsible trading and mental health, plus support for employees and their families. This initiative aims to promote responsible trading and reduce barriers to mental health care for those affected by trading-related stress or addiction.
High Roller Technologies' new behavioral health support initiative for prediction market traders is presented here with relevant health sector market data from Pluang as of Nov 06, 2026 19:41 WIB. Among 150 priced US health stocks, 52 rose and 90 fell. Notably, AMPH rose 6.47% with a typical hold time of 18 days, contrasting with FLNA's 6.21% rise but longer hold time of 39 days. HIMS showed a similar 6.44% gain and a hold time of 23 days, with a buy-heavy order activity of 65%.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
